

Kidney Cancer GCOM 13 (day 2) minutes

Kidney Cancer update – committee meeting 13 (day 2) minutes

**Date:** 25/11/2025

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>		
Ana Semedo	Vice Chair, Oncology Cancer Nurse, Committee	Present for items 1-9
Axel Bex	Urological Surgeon	Present for items 4-9
Janet Brown	Medical Oncologist	Present for partway through item 3-9
Lisa Browning	Histopathologist	Present for partway through item 2-9
Amy Clifford	Clinical Oncologist (SABR)	Present for item 5
John Connolly	Lay Member	Present for items 1-9
David Cullen	Urology Cancer Nurse	Present for items 1-9
Stuart Evans	Oncology Pharmacist	Present for items 1-9
Geraldine Fox	Lay Member	Present for items 1-9
David Mole	Nephrologist (co-opted member)	Present for items 1-9
Sandeep Singh Randhawa	General Practitioner	Present for items 1-9
Grant Stewart	Topic Adviser	Present for items 1-partway through 4, 5-9
James Whitworth	Clinical Geneticist	Present for items 1-9
Sam Withey	Diagnostic Radiologist	Present for items 1-9

<b>In attendance NICE:</b>		
Adefisayo Abba-Abba	Technical Analyst	Present for items 1-9
Sarah Boyce	Senior Technical Analyst	Present for items 1-9
Olivia Crane	Senior Technical Analyst	Present for items 1-9
Danielle Conroy	Project Manager	Present for items 1-9
Lindsay Claxton	Health Economics Adviser	Present for items 1-9
Rachel Gick	Technical Analyst, Quality Standards (observing)	Present for items 1-9
Nicola Greenway	Measurement Lead, Quality Standards (observing)	Present for items 1-9

## Kidney Cancer GCOM 13 (day 2) minutes

Marie Harrisingh	Topic Lead	Present for items 1-9
Agnesa Mehmeti	Technical Analyst	Present for items 1-9
Ellie Zachariades	Senior Guidance Content Designer	Present for items 1-9
Yuanyuan Zhang	Senior Health Economist	Present for items 1-9

### Apologies:

Victoria Carter	Implementation Support Manager, NICE
Amarnath Challapalli	Clinical Oncologist (General), Committee
Benjamin Gregory	Business Analyst, Resource Impact, NICE
Fayiza Habeeb	Lead Nurse Practitioner, Committee
Vishal Patil	Anaesthetist (co-opted member), Committee
Ankit Rao	Medical Oncologist, Committee
Katherine Saxby	Pharmacist Clinical Advisor, NICE
Baljit Singh	Chair, Committee
Maxine Tran	Urological Surgeon, Committee
Tze Min Wah	Interventional Radiologist, Committee
Rose Woodward	Lay Member, Committee

### 1. Welcome, Introductions and DOIs

The Vice Chair, Ana Semedo (AS) welcomed the committee members and NICE attendees to the second and final post-consultation committee meeting for the NICE Kidney Cancer guideline.

AS informed attendees that apologies had been received as noted above. AS asked all committee members to verbally declare any new interests.

No new interests were declared but AS reminded the group of the following recorded interests which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio;	Specific non-financial professional and	Declare and partial exclusion  Study included in the evidence base for RQ5b on

Kidney Cancer GCOM 13 (day 2) minutes

	Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	Monagas, Serenella; Williams, Samuel P; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.); <a href="#">Scandinavian journal of urology; 2019; vol. 53 (no. 1); 14-20</a>  Declared 12/24	personal	follow up however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel Paul; Torbrand, Christian; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).; <a href="#">European urology; 2019; vol. 75 (no. 2); 261-264</a>  Declared 12/24	Specific non-financial professional and personal	Declare and partial exclusion  Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	<a href="#">De Bruijn, Roderick Emile, Mulders, Peter, Jewett, Michael A et al. (2019) Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).</a> <a href="#">European urology 76(4): 437-440</a>  <a href="#">Bex, Axel, Mulders, Peter, Jewett, Michael et al. (2019) Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA oncology 5(2): 164-170</a>	Specific non-financial professional and personal	Specific  Declare and partial exclusion  Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for

Kidney Cancer GCOM 13 (day 2) minutes

		Declared 03/25		drafting recommendations.
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	<a href="#">de Groot, Saskia, Redekop, William K, Sleijfer, Stefan et al. (2016) Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.</a> Urology 95: 121-7  Declared 03/25	Specific non-financial professional and personal	Specific  Declare and partial exclusion  Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	<a href="#">Fransen van de Putte, Elisabeth E, van den Brink, Luna, Mansour, Mohamed A et al. (2023) Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?.</a> European urology open science 55: 15-22  Declared 03/25	Specific non-financial professional and personal	Specific  Declare and partial exclusion  Study included in the evidence base for RQ6 part 2 however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.
Geraldine Fox	Lay member	Trustee of Kidney Cancer UK  Declared 11/23	Specific non-financial professional and personal	Declare and partial exclusion  Can participate in discussion but excluded from decision making in response to

Kidney Cancer GCOM 13 (day 2) minutes

				Kidney Cancer UK consultation comments.
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Harrison, H., Stewart, G.D. and Usher-Smith, J.A. (2023), Patient experience of follow-up after surgery for kidney cancer: a focus group study. <i>BJU Int</i> , 132: 47-55. <a href="https://doi.org/10.1111/bju.15982">https://doi.org/10.1111/bju.15982</a>  Declared 04/25	Specific non-financial professional and personal	Declare and partial exclusion.  Included study for RQ1 on information needs.  Participate in discussion but withdraw from drafting recommendations
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H., Patki, P., Stewart, G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. <i>BJU Int</i> , 134: 796-804. <a href="https://doi.org/10.1111/bju.16470">https://doi.org/10.1111/bju.16470</a>  Declared 04/25	Specific non-financial professional and personal	Declare and partial exclusion.  Included study for RQ1 on information needs.  Participate in discussion but withdraw from drafting recommendations.
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel P; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database	Specific non-financial professional and personal	Declare and partial exclusion  Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.

Kidney Cancer GCOM 13 (day 2) minutes

	Trust	(R.E.C.U.R.); Scandinavian journal of urology; 2019; vol. 53 (no. 1); 14-20  Declared 12/24		
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel Paul; Torbrand, Christian; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR); European urology; 2019; vol. 75 (no. 2); 261-264  Declared 12/24	Specific non-financial professional and personal	Declare and partial exclusion  Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Trustee of Kidney Cancer UK  Declared 07/23	Specific non-financial professional and personal	Declare and partial exclusion  Can participate in discussion but excluded from decision making in response to Kidney Cancer UK consultation comments

Axel Bex (AB) was an author on papers included in the evidence review for RQ5b and RQ6 being discussed. It was agreed that he could remain in the room to answer questions as his expertise was required but he would need to remain silent whilst recommendations on follow-up and non-pharmacological interventions before and after systematic anti-cancer therapy were being revised.

Geraldine Fox (GF) holds a senior position at Kidney Cancer UK so was excluded from decision making in response to Kidney Cancer UK consultation comments.

Grant Stewart (GS) was an author on papers included in the evidence review for RQ1

and RQ5b being discussed. It was agreed that he could remain in the room to answer questions as his expertise was required but he would need to remain silent whilst recommendations on information needs and follow-up were being revised.

GS also holds a senior position at Kidney Cancer UK so was excluded from decision making in response to Kidney Cancer UK consultation comments.

Finally, the minutes from committee 13 (day 1) were checked and agreed to be an accurate record.

## **2. General Information**

Marie Harrisingh (MH), Topic Lead outlined the aims of the meeting and explained how the meeting will run.

The Vice Chair introduced Agnesa Mehmeti (AM), Technical Analyst who presented stakeholder feedback on general information which required further consideration and input from committee.

This covered several themes including general information needs, psychological support and Cancer Nurse Specialists.

The committee answered questions from the NICE team, discussed the comments as a group and initial revisions to recommendation wording were agreed as required.

GS withdrew from participating in revising recommendation wording on information due to a conflict of interest.

GF and GS withdrew from participating in responding to Kidney Cancer UK consultation comments in this area due to a conflict of interest.

The Vice Chair thanked MH and AM for their contribution to the meeting.

## **3. Follow up**

AS introduced Adefisayo Abba-Abba (AAA), Technical Analyst who presented the stakeholder feedback received on follow up for localised and locally advanced renal cell carcinoma.

This included the themes of discharge, testing and the schedule for follow up.

The committee answered questions from the NICE team, discussed the comments as a group and agreed whether revisions to the recommendation wording were required.

GS withdrew from participating in revision of any recommendation wording regarding follow up due to a conflict of interest.

GF and GS withdrew from participating in responding to Kidney Cancer UK

consultation comments in this area due to a conflict of interest.

The Vice Chair thanked the committee for their input.

#### **4. Imaging for diagnosis and any other imaging queries**

AAA then went on to present the stakeholder feedback received on imaging for diagnosis and follow up.

This included the themes of types of imaging and their suitability and terminology used in the guideline.

The committee answered questions from the NICE team, discussed the comments as a group and agreed whether revisions to the recommendation wording were required.

GF and GS withdrew from participating in responding to Kidney Cancer UK consultation comments in this area due to a conflict of interest.

The Vice Chair thanked the committee for their input.

#### **5. Advanced RCC**

- **Non-pharmacological management**
- **Referral**

AS introduced Olivia Crane (OC) Senior Technical Analyst, presented the stakeholder feedback received on managing advanced renal cell carcinoma that required committee input.

This covered non-pharmacological management including treating metastases and cytoreductive nephrectomy and referring people with advanced renal cell carcinoma.

The committee answered questions from the NICE team, discussed the comments as a group and agreed whether revisions to the recommendation wording were required.

AB withdrew from participating in revision of any recommendation wording regarding interventions before and after systematic anticancer therapy due to a conflict of interest.

GF and GS withdrew from participating in responding to Kidney Cancer UK consultation comments in this area due to a conflict of interest.

The Vice Chair thanked the committee for their input.

#### **6. Miscellaneous comments including MDT terminology**

OC, Sarah Boyce and MH proceeded to present any outstanding stakeholder comments that the NICE team required committee input on.

The committee answered questions from the NICE team, discussed the comments as a group and agreed whether revisions to the recommendation wording were required.

The Vice Chair thanked the committee for their input.

### **7. Research Recommendations**

The Vice Chair introduced Marie Harrisingh (MH), Topic Lead, who presented the current recommendations for research for further committee consideration.

The committee answered questions from the NICE team and agreed whether any changes were required.

The Chair thanked the committee for their input.

### **8. Next steps**

The Vice Chair introduced Danielle Conroy (DC), Project Manager who explained, as this was the last meeting, what will happen next, including key dates and NICE processes leading up to publication of the final guideline.

### **9. Next steps and AOB**

AS summarised the main actions from the day and thanked the committee and NICE team for their hard work and commitment over the last couple of years.

AS asked for items of any other business. As there was no further business to discuss, AS brought the meeting to a close.

**Date of next meeting:** N/A

**Location of next meeting:** N/A